The two new drugs, tocilizumab and sarilumab, typically used to treat rheumatoid arthritis, are monoclonal antibodies that target a protein called interleukin-6, which is thought to be important in the COVID-19 infection pathway.
The drugs have shown effectiveness for patients requiring organ support, according to the Department of Health and Social Care (DHSC).
Deputy Chief Medical Officer for England Jonathan Van-Tam said that data from a clinical trial showed that the drugs can speed up and improve the odds of recovery in intensive care.
According to the DHSC, the REMAP-CAP analysis, which has not yet been peer-reviewed, also indicated that patients who received either one of these drugs left intensive care on average between 7 and 10 days earlier than those who didn’t.
“Most of the data came from when the drugs were administered in addition to a corticosteroid, such as dexamethasone,” DHSC said.
Speaking at a televised briefing on Thursday, Prime Minister Boris Johnson said the drugs “will be available through the NHS with immediate effect, potentially saving thousands of lives.”
The statement said data showed a high dose of tocilizumab has been shown to increase risk of spontaneous abortion/embryofoetal death in animal trials, but there isn’t enough data to assess its potential risk to humans.